Twenty-six percent of breast cancers and 12% of large intestinal cancers have somatic mutations to PIK3CA [13], making mutant PIK3CA a popular target for the development of chemotherapeutic agents [14]. This evidence concerns the gene PIK3CA and breast cancer.